Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

RATIONALE: Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more effective than a placebo in preventing melanoma in individuals with many moles and abnormal moles.

PURPOSE: This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma.

Further Study Information

OBJECTIVES:

Primary

• Determine sulindac and metabolite levels in healthy participants with atypical nevi and benign nevus at increased risk for melanoma treated with sulindac versus placebo.

Secondary

• Assess the effects of sulindac on apoptosis in atypical nevi of these participants.

• Assess the effects of sulindac on VEGF expression in atypical nevi of these participants.

• Assess sulindac and metabolite levels in plasma and its association with drug levels in the target tissue.

OUTLINE: This is a multicenter study. Participants are randomized to 1 of 2 treatment arms.

• Arm I: Participants receive oral sulindac twice daily.

• Arm II: Participants receive oral placebo twice daily. In both arms, treatment continues for 8 weeks in the absence of unacceptable toxicity.

Blood and tissue samples are collected at baseline and/or after completion of study therapy and analyzed for sulindac and metabolite levels via high performance liquid chromatography tandem mass spectrometry; the detection of apoptotic cells via TUNEL assay; and VEGF expression via immunohistochemistry assays.

After completion of study therapy, participants are followed for 2 weeks.

Eligibility Criteria

DISEASE CHARACTERISTICS:

• Healthy participants at risk for developing melanoma and meeting the following criteria:

• Must have ≥ 4 large (≥ 5 mm and < 15 mm) atypical nevi

• Must have 1 benign nevus amenable to biopsies

• No histologically confirmed melanoma on the baseline biopsy

• No more than 1 prior cutaneous melanoma

• One prior stage I, IIA, or IIB melanoma allowed provided patients have been off treatment > 3 months

• No family history of melanoma involving ≥ 2 first degree relatives

• Modified dermoscopy score < 4.8

PATIENT CHARACTERISTICS:

• Karnofsky performance status 80-100%

• WBC ≥ 3,000/mm³

• ANC ≥ 1,500/mm³

• Platelets count ≥ 100,000/mm³

• Total bilirubin ≤ 2.0 mg/dL

• AST/ALT ≤ 2.0 times upper limit of normal

• Creatinine ≤ 1.5 mg/dL

• Not pregnant or nursing

• Fertile patients must use effective contraception

• More than 6 months since prior and no concurrent tanning bed use or other methods to promote sun-tanning

• Willing to minimize sunlight exposure by applying sunscreen/sunblock or wearing clothing to shield skin during outdoor activity during study participation

• Willing or able to limit alcohol consumption to less than 3 servings a week during the study period

• No frequent, chronic or moderate/severe gastrointestinal (GI) complaints including, but not limited to, any of the following:

• Upper GI problems requiring prescription or nonprescription medical remedies for symptoms of heartburn, dyspepsia, nausea, or abdominal pain > once a week on average

• History of peptic ulcer, occult or gross intestinal bleeding

• No prior allergic reaction to aspirin (unless subsequent dosing with other NSAIDs has been well tolerated)

• No history of allergic reaction to lidocaine or xylocaine

• No history of allergic reaction (e.g., urticaria, asthma, or rhinitis) or gastric intolerance attributed to compounds of similar chemical or biological composition to sulindac

• No history of bleeding or clotting disorder

• No invasive cancer or cancer treatment within the past 5 years, except nonmelanoma skin cancer

• No immunosuppression by medication or disease, including any of the following:

• AIDS

• Oral prednisone

• Immunosuppressant/immunomodulator (i.e., cyclosporine, chemotherapeutic agent, or biologic therapy)

• No uncontrolled intercurrent illness including, but not limited to, any of the following:

• Ongoing or active infection

• Symptomatic congestive heart failure

• Unstable angina pectoris

• Cardiac arrhythmia

• Psychiatric illness/social situations that would limit compliance with study requirements

PRIOR CONCURRENT THERAPY:

• At least 3 months since prior and no concurrent coumadin or other systemic anticoagulant other than aspirin

• At least 30 days since prior participation and no concurrent enrollment or planning to enroll in another clinical trial

• No NSAIDs for more than 5 days per month within the past 3 months and no concurrent non-study NSAIDs, except low dose aspirin (81 mg/day)

• Willing or able to refrain from herbal medicines, above-standard vitamins, or minerals during study

• Standard daily multivitamin/mineral supplement (i.e., therapeutic doses of calcium and vitamin D for osteoporosis) allowed

• No concurrent lithium, phenytoin, or sulfonamides

Trial Contact Information

Trial Lead Organizations/Sponsors

National Cancer Institute

H. H. Sherry Chow

Study Chair

Clara Curiel

Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00841204
Information obtained from ClinicalTrials.gov on December 14, 2011

Back to Top